BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 1514528)

  • 1. Deferoxamine, cyclophosphamide, etoposide, carboplatin, and thiotepa (D-CECaT): a new cytoreductive chelation-chemotherapy regimen in patients with advanced neuroblastoma.
    Donfrancesco A; Deb G; Dominici C; Angioni A; Caniglia M; De Sio L; Fidani P; Amici A; Helson L
    Am J Clin Oncol; 1992 Aug; 15(4):319-22. PubMed ID: 1514528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deferoxamine followed by cyclophosphamide, etoposide, carboplatin, thiotepa, induction regimen in advanced neuroblastoma: preliminary results. Italian Neuroblastoma Cooperative Group.
    Donfrancesco A; De Bernardi B; Carli M; Mancini A; Nigro M; De Sio L; Casale F; Bagnulo S; Helson L; Deb G
    Eur J Cancer; 1995; 31A(4):612-5. PubMed ID: 7576980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. D-CECaT: a breakthrough for patients with neuroblastoma.
    Donfrancesco A; Deb G; Angioni A; Maurizio C; Cozza R; Jenkner A; Landolfo A; Boglino C; Helson L
    Anticancer Drugs; 1993 Jun; 4(3):317-21. PubMed ID: 8395258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. D-CECaT as preoperative chemotherapy for unresectable neuroblastoma in children over one year of age.
    Donfrancesco A; Deb G; Dominici C; De Sio L; Inserra A; Boglino C; Takahashi M; Uchino J; Helson L
    Anticancer Res; 1995; 15(5B):2347-50. PubMed ID: 8572650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results of induction chemotherapy in children older than 18 months with stage-4 neuroblastoma treated with an adaptive-to-response modified N7 protocol (mN7).
    Mora J; Cruz O; Lavarino C; Rios J; Vancells M; Parareda A; Salvador H; Suñol M; Carrasco R; Guillen A; Mañé S; de Torres C
    Clin Transl Oncol; 2015 Jul; 17(7):521-9. PubMed ID: 25596034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. OPEC/OJEC for stage 4 neuroblastoma in children over 1 year of age.
    Tweddle DA; Pinkerton CR; Lewis IJ; Ellershaw C; Cole M; Pearson AD
    Med Pediatr Oncol; 2001 Jan; 36(1):239-42. PubMed ID: 11464894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short topotecan-based induction regimen in newly diagnosed high-risk neuroblastoma.
    De Ioris MA; Castellano A; Ilari I; Garganese MC; Natali G; Inserra A; De Vito R; Ravà L; De Pasquale MD; Locatelli F; Donfrancesco A; Jenkner A
    Eur J Cancer; 2011 Mar; 47(4):572-8. PubMed ID: 21112775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose-intensive use of cyclophosphamide in ablation of neuroblastoma.
    Kushner BH; O'Reilly RJ; LaQuaglia M; Cheung NK
    Cancer; 1990 Sep; 66(6):1095-100. PubMed ID: 2400963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autografting with bone marrow exposed to multiple courses of very high dose cyclophosphamide in vivo and to 4-hydroperoxycyclophosphamide in vitro.
    Kushner BH; Gulati SC; O'Reilly RJ; Heller G; Cheung NK
    Med Pediatr Oncol; 1990; 18(6):454-8. PubMed ID: 2135871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined continuous infusion etoposide with high-dose cyclophosphamide for refractory neuroblastoma: a phase II study from the Société Française d'Oncologie Pédiatrique.
    Méresse V; Vassal G; Michon J; De Cervens C; Courbon B; Rubie H; Perel Y; Landman J; Chastagnier P; De Valck C
    J Clin Oncol; 1993 Apr; 11(4):630-7. PubMed ID: 8478658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pilot study of high-dose vincristine, etoposide, carboplatin and melphalan with autologous bone marrow rescue in advanced neuroblastoma.
    Corbett R; Pinkerton R; Pritchard J; Meller S; Lewis I; Kingston J; McElwain T
    Eur J Cancer; 1992; 28A(8-9):1324-8. PubMed ID: 1515243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ifosfamide/carboplatin/etoposide (ICE) as front-line, topotecan/cyclophosphamide as second-line and oral temozolomide as third-line treatment for advanced neuroblastoma over one year of age.
    Donfrancesco A; Jenkner A; Castellano A; Ilari I; Milano GM; De Sio L; Cozza R; Fidani P; Deb G; De Laurentis C; Inserra A; Dominici C
    Acta Paediatr Suppl; 2004 May; 93(445):6-11. PubMed ID: 15176712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II investigational window using carboplatin, iproplatin, ifosfamide, and epirubicin in children with untreated disseminated neuroblastoma: a Pediatric Oncology Group study.
    Castleberry RP; Cantor AB; Green AA; Joshi V; Berkow RL; Buchanan GR; Leventhal B; Mahoney DH; Smith EI; Hayes FA
    J Clin Oncol; 1994 Aug; 12(8):1616-20. PubMed ID: 8040674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topotecan combined with myeloablative doses of thiotepa and carboplatin for neuroblastoma, brain tumors, and other poor-risk solid tumors in children and young adults.
    Kushner BH; Cheung NK; Kramer K; Dunkel IJ; Calleja E; Boulad F
    Bone Marrow Transplant; 2001 Sep; 28(6):551-6. PubMed ID: 11607767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A study of thiotepa, etoposide and fractionated total body irradiation as a preparative regimen prior to bone marrow transplantation for poor prognosis patients with neuroblastoma.
    Kamani N; August CS; Bunin N; Leahey A; Bayever E; Goldwein J; Zusman J; Evans AE; Angio GD
    Bone Marrow Transplant; 1996 Jun; 17(6):911-6. PubMed ID: 8807093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serial intense chemotherapy combining topotecan, etoposide, carboplatin and cyclophosphamide (TECC) followed by autologous hematopoietic stem cell support in patients with high risk soft tissue sarcoma (STS).
    Bernbeck B; Bahci S; Meisel R; Troeger A; Schönberger S; Laws HJ; Kramm C; Wessalowski R; Koscielniak E; Dilloo D; Göbel U
    Klin Padiatr; 2007; 219(6):318-22. PubMed ID: 18050041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of a multi-course high-dose chemotherapy regimen incorporating cyclophosphamide, thiotepa, and carboplatin in stage IV breast cancer.
    Schrama JG; Baars JW; Holtkamp MJ; Schornagel JH; Beijnen JH; Rodenhuis S
    Bone Marrow Transplant; 2001 Jul; 28(2):173-80. PubMed ID: 11509935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. No salvage using high-dose chemotherapy plus/minus reirradiation for relapsing previously irradiated medulloblastoma.
    Massimino M; Gandola L; Spreafico F; Biassoni V; Luksch R; Collini P; Solero CN; Simonetti F; Pignoli E; Cefalo G; Poggi G; Modena P; Mariani L; Potepan P; Podda M; Casanova M; Pecori E; Acerno S; Ferrari A; Terenziani M; Meazza C; Polastri D; Ravagnani F; Fossati-Bellani F
    Int J Radiat Oncol Biol Phys; 2009 Apr; 73(5):1358-63. PubMed ID: 19019566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age.
    Kushner BH; LaQuaglia MP; Bonilla MA; Lindsley K; Rosenfield N; Yeh S; Eddy J; Gerald WL; Heller G; Cheung NK
    J Clin Oncol; 1994 Dec; 12(12):2607-13. PubMed ID: 7527454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multimodal strategy based on surgery, radiotherapy, ICE regimen and high dose chemotherapy in atypical teratoid/rhabdoid tumours: a single institution experience.
    Fidani P; De Ioris MA; Serra A; De Sio L; Ilari I; Cozza R; Boldrini R; Milano GM; Garrè ML; Donfrancesco A
    J Neurooncol; 2009 Apr; 92(2):177-83. PubMed ID: 19048188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.